What is Merit Med Sys Inc's earnings per share (EPS)?

Merit Med Sys Inc (MMSI) reported diluted earnings per share of $2.13 for fiscal year 2025. This represents a 4.9% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Merit Med Sys Inc Financials

MMSI

Trailing 12 months to June 30, 2026

Revenue $1.6B +10.2% YoY

Net Income $145.6M +22.2% YoY

EPS (Diluted) $2.43 +23.4% YoY

Free Cash Flow $203.2M +5.7% YoY

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Jul 30, 2026 Currency USD FYE December

Merit Med Sys Inc (MMSI) reported $1.6B in revenue over the twelve months to Jun 30, 2026, up 10.2% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI MMSI FY2025 2026-04-30

A steady margin expansion story has turned rising sales into disproportionately higher cash generation despite a still meaningful debt load.

The least obvious shift is cash conversion quality: from FY2023 to FY2025, operating cash flow rose from $145M to $297M while net income moved from $94M to $128M. Because long-term debt stayed near $730M and the current ratio remained above 4x, the stronger liquidity now looks increasingly earned by operations rather than dependent on new financing.

Gross margin widened from 45.2% in FY2021 to 48.7% in FY2025, and operating margin more than doubled from 5.7% to 12.2%, which means added gross profit is flowing through the cost structure more efficiently. Even with R&D up to $97M and capital spending at $82M in FY2025, the business is keeping more of each sales dollar before and after reinvestment.

The balance sheet still carries a large intangible-and-debt footprint: goodwill reached $507M and long-term debt is $734M, even though cash improved to $446M and the current ratio stayed at 4.3x. Inventory and receivables became a slightly smaller share of revenue than in FY2023, which helps explain why free cash flow held at $216M despite higher capex.

Financial Health Signals

Financial Health Score 69/100

Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Merit Med Sys Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

Merit Med Sys Inc has an operating margin of 12.2%, meaning the company retains $12 of operating profit per $100 of revenue. This strong profitability earns a score of 72/100, reflecting efficient cost management and pricing power. This is up from 11.5% the prior year.

Growth

Merit Med Sys Inc's revenue grew 11.8% year-over-year to $1.5B, a solid pace of expansion. This earns a growth score of 65/100.

Leverage

Merit Med Sys Inc has a moderate D/E ratio of 0.46. This balance of debt and equity financing earns a leverage score of 47/100.

Liquidity

With a current ratio of 4.34, Merit Med Sys Inc holds $4.34 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 87/100.

Cash Flow

Merit Med Sys Inc converts 14.2% of revenue into free cash flow ($215.7M). This strong cash generation earns a score of 75/100.

Returns

Merit Med Sys Inc earns a strong 8.1% return on equity (ROE), meaning it generates $8 of profit for every $100 of shareholders' equity. This efficient capital use earns a returns score of 66/100. This is down from 8.7% the prior year.

Altman Z-Score Safe

4.49

Merit Med Sys Inc scores 4.49, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($5.3B) relative to total liabilities ($1.1B). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Strong

7/9

Merit Med Sys Inc passes 7 of 9 financial strength tests. 3 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Cash-Backed

2.31x

For every $1 of reported earnings, Merit Med Sys Inc generates $2.31 in operating cash flow ($297.4M OCF vs $128.5M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Interest Coverage Safe

6.98x

Merit Med Sys Inc earns $6.98 in operating income for every $1 of interest expense ($184.7M vs $26.5M). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$1.5B

YoY+11.8%

5Y CAGR+9.5%

10Y CAGR+10.8%

Merit Med Sys Inc generated $1.5B in revenue in fiscal year 2025. This represents an increase of 11.8% from the prior year.

EBITDA

$307.9M

YoY+19.2%

5Y CAGR+27.2%

10Y CAGR+15.2%

Merit Med Sys Inc's EBITDA was $307.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 19.2% from the prior year.

Net Income

$128.5M

YoY+6.8%

10Y CAGR+18.4%

Merit Med Sys Inc reported $128.5M in net income in fiscal year 2025. This represents an increase of 6.8% from the prior year.

EPS (Diluted)

$2.13

YoY+4.9%

10Y CAGR+14.9%

Merit Med Sys Inc earned $2.13 per diluted share (EPS) in fiscal year 2025. This represents an increase of 4.9% from the prior year.

Cash & Balance Sheet

Free Cash Flow

$215.7M

YoY+16.2%

5Y CAGR+12.6%

10Y CAGR+27.8%

Merit Med Sys Inc generated $215.7M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 16.2% from the prior year.

Cash & Debt

$446.4M

YoY+18.5%

5Y CAGR+51.0%

10Y CAGR+59.5%

Merit Med Sys Inc held $446.4M in cash against $734.0M in long-term debt as of fiscal year 2025.

Shares Outstanding

59M

YoY+1.0%

5Y CAGR+1.3%

10Y CAGR+3.0%

Merit Med Sys Inc had 59M shares outstanding in fiscal year 2025. This represents an increase of 1.0% from the prior year.

Dividends Per Share

Not reported for fiscal year 2025.

Margins & Returns

Gross Margin

48.7%

YoY+1.3pp

5Y CAGR+7.1pp

10Y CAGR+5.2pp

Merit Med Sys Inc's gross margin was 48.7% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 1.3 percentage points from the prior year.

Operating Margin

12.2%

YoY+0.7pp

5Y CAGR+12.3pp

10Y CAGR+5.3pp

Merit Med Sys Inc's operating margin was 12.2% in fiscal year 2025, reflecting core business profitability. This is up 0.7 percentage points from the prior year.

Net Margin

8.5%

YoY-0.4pp

5Y CAGR+9.5pp

10Y CAGR+4.1pp

Merit Med Sys Inc's net profit margin was 8.5% in fiscal year 2025, showing the share of revenue converted to profit. This is down 0.4 percentage points from the prior year.

Return on Equity

8.1%

YoY-0.6pp

5Y CAGR+9.1pp

10Y CAGR+3.0pp

Merit Med Sys Inc's ROE was 8.1% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 0.6 percentage points from the prior year.

Capital Allocation

R&D Spending

$97.4M

YoY+11.3%

5Y CAGR+11.1%

10Y CAGR+9.1%

Merit Med Sys Inc invested $97.4M in research and development in fiscal year 2025. This represents an increase of 11.3% from the prior year.

Capital Expenditures

$81.7M

YoY+132.5%

5Y CAGR+12.2%

10Y CAGR+4.8%

Merit Med Sys Inc invested $81.7M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 132.5% from the prior year.

Share Buybacks

Not reported for fiscal year 2025.

MMSI Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

MMSI quarterly income statement

Metric	TTM	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Revenue	$1.6B	$1.5B+11.8%	$1.4B+7.9%	$1.3B+9.2%	$1.2B+7.1%	$1.1B+11.5%	$963.9M-3.1%	$994.9M+12.7%	$882.8M+21.3%	$727.9M+20.5%	$603.8M+11.4%	$542.1M+6.4%	$509.7M+13.5%	$449.0M+13.9%	$394.3M+9.7%	$359.4M
Cost of Revenue	$797.1M	$777.6M+9.0%	$713.2M+5.9%	$673.5M+6.6%	$631.9M+7.2%	$589.4M+4.7%	$562.7M0.0%	$562.5M+15.3%	$488.0M+21.5%	$401.6M+18.5%	$338.8M+10.6%	$306.4M+7.7%	$284.5M+11.7%	$254.7M+20.0%	$212.3M+9.4%	$194.0M
Gross Profit	$781.7M	$738.3M+14.8%	$643.3M+10.2%	$583.9M+12.5%	$519.1M+7.0%	$485.3M+21.0%	$401.2M-7.2%	$432.4M+9.5%	$394.8M+21.0%	$326.3M+23.1%	$265.0M+12.4%	$235.8M+4.7%	$225.2M+15.9%	$194.4M+6.8%	$182.0M+10.0%	$165.5M
R&D Expenses	$98.5M	$97.4M+11.3%	$87.5M+5.7%	$82.7M+9.6%	$75.5M+6.0%	$71.2M+23.8%	$57.5M-12.3%	$65.6M+10.2%	$59.5M+15.8%	$51.4M+13.7%	$45.2M+10.8%	$40.8M+11.4%	$36.6M+8.1%	$33.9M+21.9%	$27.8M+26.7%	$21.9M
SG&A Expenses	$482.1M	$455.2M+13.9%	$399.7M+7.0%	$373.7M+9.1%	$342.5M+2.0%	$335.7M+12.8%	$297.7M-9.0%	$327.3M+18.6%	$276.0M+20.5%	$229.1M+24.3%	$184.4M+17.9%	$156.3M+5.7%	$147.9M+15.0%	$128.6M+5.4%	$122.1M+16.8%	$104.5M
Operating Income	$201.4M	$184.7M+18.6%	$155.7M+25.6%	$123.9M+41.5%	$87.6M+43.7%	$60.9M+3999.9%	-$1.6M-110.1%	$15.4M-73.7%	$58.6M+77.3%	$33.1M-5.2%	$34.9M-7.1%	$37.5M-6.5%	$40.2M+44.3%	$27.8M-6.1%	$29.6M-10.7%	$33.2M
Interest Expense	$31.8M	$26.5M-15.2%	$31.2M+101.3%	$15.5M+144.7%	$6.3M+20.5%	$5.3M-47.4%	$10.0M-19.5%	$12.4M+19.8%	$10.4M+33.9%	$7.7M-12.1%	$8.8M+41.2%	$6.2M-29.4%	$8.8M+9.8%	$8.0M+1231.8%	$604K-23.4%	$789K
Income Tax	$48.9M	$42.4M+43.2%	$29.6M+67.6%	$17.7M+117.9%	$8.1M+48.5%	$5.5M+261.2%	-$3.4M-4.0%	-$3.3M-143.4%	$7.5M-10.2%	$8.4M+58.7%	$5.3M-28.8%	$7.4M-14.0%	$8.6M+163.0%	$3.3M-58.7%	$7.9M-19.6%	$9.8M
Net Income	$145.6M	$128.5M+6.8%	$120.4M+27.5%	$94.4M+26.7%	$74.5M+53.8%	$48.5M+592.3%	-$9.8M-280.6%	$5.5M-87.0%	$42.0M+52.7%	$27.5M+36.8%	$20.1M-15.5%	$23.8M+3.6%	$23.0M+38.6%	$16.6M-15.9%	$19.7M-14.5%	$23.0M
EPS (Diluted)	$2.43	$2.13+4.9%	$2.03+25.3%	$1.62+25.6%	$1.29+53.6%	$0.84+566.7%	-$0.18-280.0%	$0.10-87.2%	$0.78+41.8%	$0.55+22.2%	$0.45-15.1%	$0.530.0%	$0.53+35.9%	$0.39-15.2%	$0.46-20.7%	$0.58

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Revenue	$418.8M+9.7%	$381.9M-3.1%	$393.9M+2.5%	$384.2M+0.4%	$382.5M+7.6%	$355.4M+0.1%	$355.2M+4.5%	$339.8M
Cost of Revenue	$203.7M+3.3%	$197.1M-0.8%	$198.6M+0.4%	$197.7M-0.1%	$198.0M+8.0%	$183.3M+0.6%	$182.2M-0.1%	$182.3M
Gross Profit	$215.2M+16.4%	$184.8M-5.4%	$195.4M+4.8%	$186.4M+1.0%	$184.5M+7.2%	$172.0M-0.6%	$173.0M+9.8%	$157.5M
R&D Expenses	$25.4M+12.3%	$22.6M-14.8%	$26.5M+10.7%	$24.0M-1.6%	$24.4M+8.4%	$22.5M-10.8%	$25.2M+22.7%	$20.5M
SG&A Expenses	$129.2M+9.3%	$118.2M+2.9%	$114.8M-4.1%	$119.8M+5.9%	$113.1M+5.2%	$107.5M-3.2%	$111.1M+11.5%	$99.6M
Operating Income	$60.4M+36.8%	$44.2M-18.5%	$54.2M+27.2%	$42.6M-9.1%	$46.9M+14.2%	$41.0M+12.2%	$36.6M-1.9%	$37.3M
Interest Expense	$12.1M+85.7%	$6.5M+2.5%	$6.4M-5.8%	$6.8M-0.3%	$6.8M+3.2%	$6.6M-17.8%	$8.0M+6.6%	$7.5M
Income Tax	$12.5M-0.3%	$12.6M-3.9%	$13.1M+21.0%	$10.8M-0.1%	$10.8M+38.2%	$7.8M+50.3%	$5.2M-36.7%	$8.2M
Net Income	$38.8M-5.3%	$41.0M+7.9%	$38.0M+36.9%	$27.8M-14.8%	$32.6M+8.1%	$30.1M+7.9%	$27.9M-1.7%	$28.4M
EPS (Diluted)	$0.65-4.4%	$0.68+6.3%	$0.64+39.1%	$0.46-14.8%	$0.54+10.2%	$0.49+6.5%	$0.46-4.2%	$0.48

MMSI Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

MMSI quarterly balance sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Total Assets	$2.7B+11.1%	$2.4B+4.0%	$2.3B+39.7%	$1.7B+1.0%	$1.6B-1.0%	$1.7B-5.3%	$1.8B+8.5%	$1.6B+45.7%	$1.1B+17.9%	$942.8M+21.1%	$778.7M+4.2%	$747.2M+2.6%	$728.3M+3.3%	$705.3M+57.8%	$447.0M
Current Assets	$1.0B+12.6%	$923.8M-16.7%	$1.1B+109.5%	$529.1M+9.7%	$482.2M+12.2%	$429.7M-5.5%	$454.5M+5.7%	$429.8M+36.0%	$316.1M+29.9%	$243.4M+19.3%	$204.0M+6.1%	$192.3M+15.9%	$165.9M+2.4%	$162.0M+21.2%	$133.7M
Cash & Equivalents	$446.4M+18.5%	$376.7M-35.8%	$587.0M+905.1%	$58.4M-13.8%	$67.8M+19.0%	$56.9M+28.4%	$44.3M-34.2%	$67.4M+108.3%	$32.3M+68.7%	$19.2M+359.0%	$4.2M-43.2%	$7.4M-1.4%	$7.5M-23.3%	$9.7M-4.0%	$10.1M
Inventory	$333.7M+9.0%	$306.1M+0.7%	$303.9M+14.2%	$266.0M+19.9%	$221.9M+12.1%	$198.0M-12.3%	$225.7M+14.3%	$197.5M+27.2%	$155.3M+28.7%	$120.7M+13.9%	$106.0M+15.5%	$91.8M+11.4%	$82.4M-2.6%	$84.6M+21.0%	$69.9M
Accounts Receivable	$203.7M+7.1%	$190.2M+6.9%	$177.9M+8.0%	$164.7M+8.1%	$152.3M+3.9%	$146.6M-5.6%	$155.4M+13.3%	$137.2M+30.0%	$105.5M+31.1%	$80.5M+14.6%	$70.3M-3.3%	$72.7M+20.8%	$60.2M+12.7%	$53.4M+31.7%	$40.5M
Goodwill	$506.8M+9.3%	$463.5M+21.3%	$382.2M+6.2%	$359.8M-0.5%	$361.7M-0.5%	$363.5M+2.9%	$353.2M+5.3%	$335.4M+40.9%	$238.1M+12.4%	$211.9M+14.9%	$184.5M0.0%	$184.5M0.0%	$184.5M+5.4%	$175.1M+186.4%	$61.1M
Total Liabilities	$1.1B+6.0%	$1.0B-7.5%	$1.1B+116.2%	$519.6M-14.6%	$608.5M-13.8%	$705.8M-12.6%	$807.4M+17.5%	$687.2M+57.8%	$435.5M-2.1%	$444.6M+42.2%	$312.6M+0.2%	$311.9M-3.3%	$322.6M-0.4%	$323.7M+260.0%	$89.9M
Current Liabilities	$239.8M+10.8%	$216.4M+6.3%	$203.6M-7.7%	$220.6M-6.6%	$236.3M+27.7%	$185.0M+1.8%	$181.7M+3.6%	$175.3M+51.7%	$115.6M+30.9%	$88.3M+0.5%	$87.9M+16.5%	$75.4M+15.0%	$65.6M-10.2%	$73.0M+66.7%	$43.8M
Long-Term Debt	$734.0M+0.6%	$729.6M-11.4%	$823.0M+340.7%	$186.8M-20.3%	$234.4M-31.8%	$343.7M-20.4%	$432.0M+15.8%	$373.2M+44.1%	$259.0M-17.6%	$314.4M+59.1%	$197.6M-7.9%	$214.5M-10.2%	$238.9M+5.0%	$227.6M+640.4%	$30.7M
Total Equity	$1.6B+14.9%	$1.4B+14.8%	$1.2B+5.0%	$1.1B+10.1%	$1.0B+8.5%	$958.6M+0.9%	$949.9M+1.8%	$932.8M+37.9%	$676.3M+35.8%	$498.2M+6.9%	$466.1M+7.1%	$435.3M+7.3%	$405.7M+6.3%	$381.6M+6.9%	$357.1M
Retained Earnings	$824.0M+18.5%	$695.5M+20.9%	$575.2M+19.6%	$480.8M+18.3%	$406.3M+13.5%	$357.8M-2.8%	$368.2M+1.3%	$363.4M+13.1%	$321.4M+9.4%	$293.9M+7.3%	$273.8M+9.5%	$250.0M+10.1%	$227.0M+7.9%	$210.4M+10.3%	$190.7M

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Total Assets	$2.9B+5.3%	$2.7B+1.2%	$2.7B+2.1%	$2.6B+1.7%	$2.6B+4.8%	$2.5B+2.0%	$2.4B+1.7%	$2.4B
Current Assets	$1.1B+0.9%	$1.1B+5.9%	$1.0B+5.5%	$985.5M+6.8%	$923.1M-3.7%	$958.6M+3.8%	$923.8M-14.3%	$1.1B
Cash & Equivalents	$448.7M-8.1%	$488.1M+9.3%	$446.4M+13.7%	$392.5M+14.8%	$341.8M-13.6%	$395.5M+5.0%	$376.7M-28.0%	$523.1M
Inventory	$374.1M+6.2%	$352.4M+5.6%	$333.7M+2.2%	$326.6M+1.0%	$323.3M+1.7%	$317.9M+3.9%	$306.1M-1.4%	$310.5M
Accounts Receivable	$224.2M+8.6%	$206.4M+1.3%	$203.7M-3.1%	$210.3M+3.0%	$204.2M+2.3%	$199.6M+4.9%	$190.2M+0.2%	$189.8M
Goodwill	$539.8M+7.2%	$503.4M-0.7%	$506.8M-0.1%	$507.4M+0.6%	$504.6M+8.7%	$464.4M+0.2%	$463.5M+16.0%	$399.4M
Total Liabilities	$1.2B+8.4%	$1.1B-0.8%	$1.1B0.0%	$1.1B+0.3%	$1.1B+5.6%	$1.0B0.0%	$1.0B-1.5%	$1.1B
Current Liabilities	$264.9M+22.2%	$216.9M-9.5%	$239.8M+4.0%	$230.5M+2.2%	$225.6M+14.6%	$196.8M-9.0%	$216.4M+7.6%	$201.1M
Long-Term Debt	$736.3M+0.1%	$735.2M+0.2%	$734.0M+0.2%	$732.9M+0.2%	$731.8M+0.2%	$730.7M+0.2%	$729.6M-2.8%	$750.5M
Total Equity	$1.7B+3.3%	$1.6B+2.7%	$1.6B+3.6%	$1.5B+2.8%	$1.5B+4.2%	$1.4B+3.6%	$1.4B+4.2%	$1.3B
Retained Earnings	$903.8M+4.5%	$865.0M+5.0%	$824.0M+4.8%	$786.0M+3.7%	$758.3M+4.5%	$725.7M+4.3%	$695.5M+4.2%	$667.6M

MMSI Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

MMSI quarterly cash flow statement

Metric	TTM	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Operating Cash Flow	$283.4M	$297.4M+34.7%	$220.8M+52.1%	$145.2M+27.0%	$114.3M-22.4%	$147.2M-10.9%	$165.3M+112.4%	$77.8M-10.1%	$86.5M+38.0%	$62.7M+17.0%	$53.6M-22.8%	$69.5M+30.3%	$53.3M+3.8%	$51.4M+9.4%	$46.9M+38.0%	$34.0M
Capital Expenditures	$80.2M	$81.7M+132.5%	$35.1M+2.5%	$34.3M-23.8%	$45.0M+61.2%	$27.9M-39.2%	$46.0M-41.2%	$78.2M+23.4%	$63.3M+64.0%	$38.6M+17.6%	$32.8M-35.6%	$51.0M+49.1%	$34.2M-42.6%	$59.5M-7.9%	$64.6M+9.2%	$59.2M
Free Cash Flow	$203.2M	$215.7M+16.2%	$185.7M+67.5%	$110.9M+60.1%	$69.3M-41.9%	$119.3M0.0%	$119.3M+33233.9%	-$360K-101.6%	$23.2M-3.7%	$24.1M+16.1%	$20.8M+12.2%	$18.5M-3.4%	$19.1M+335.4%	-$8.1M+54.1%	-$17.7M+29.7%	-$25.2M
Investing Cash Flow	-$176.8M	-$247.4M+32.9%	-$368.7M-110.2%	-$175.3M-205.5%	-$57.4M-54.5%	-$37.2M+36.6%	-$58.7M+56.4%	-$134.5M+64.5%	-$378.8M-158.1%	-$146.8M+7.8%	-$159.1M-156.5%	-$62.0M-71.3%	-$36.2M+47.2%	-$68.6M+73.2%	-$255.6M-245.3%	-$74.0M
Financing Cash Flow	-$644K	$16.0M+126.7%	-$60.0M-110.7%	$559.3M+1028.1%	-$60.3M+38.8%	-$98.4M-2.9%	-$95.7M-385.4%	$33.5M-89.8%	$328.3M+240.1%	$96.5M-20.3%	$121.1M+1283.1%	-$10.2M+39.7%	-$17.0M-214.9%	$14.8M-92.9%	$208.3M+346.1%	$46.7M
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Cash Flow	$69.3M+70.3%	$40.7M-58.7%	$98.5M+31.4%	$75.0M-10.0%	$83.3M+105.3%	$40.6M-41.0%	$68.7M+45.2%	$47.3M
Capital Expenditures	$17.3M+8.3%	$16.0M-34.6%	$24.5M+9.0%	$22.4M+63.2%	$13.8M-34.7%	$21.1M+506.6%	$3.5M-62.9%	$9.4M
Free Cash Flow	$51.9M+110.5%	$24.7M-66.7%	$74.0M+40.9%	$52.5M-24.5%	$69.6M+256.5%	$19.5M-70.1%	$65.3M+71.9%	$38.0M
Investing Cash Flow	-$110.1M-1524.0%	$7.7M+115.4%	-$50.3M-109.2%	-$24.1M+83.2%	-$143.4M-383.7%	-$29.6M+86.2%	-$214.4M-85.4%	-$115.7M
Financing Cash Flow	$948K+115.1%	-$6.3M-224.2%	$5.1M+1486.8%	-$365K-108.4%	$4.3M-37.5%	$7.0M+186.0%	$2.4M+105.1%	-$47.6M

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

MMSI Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples.

MMSI quarterly financial ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Gross Margin	48.7%+1.3pp	47.4%+1.0pp	46.4%+1.3pp	45.1%-0.1pp	45.2%+3.5pp	41.6%-1.8pp	43.5%-1.3pp	44.7%-0.1pp	44.8%+0.9pp	43.9%+0.4pp	43.5%-0.7pp	44.2%+0.9pp	43.3%-2.9pp	46.2%+0.1pp	46.0%
Operating Margin	12.2%+0.7pp	11.5%+1.6pp	9.9%+2.2pp	7.6%+1.9pp	5.7%+5.8pp	-0.2%-1.7pp	1.6%-5.1pp	6.6%+2.1pp	4.5%-1.2pp	5.8%-1.1pp	6.9%-1.0pp	7.9%+1.7pp	6.2%-1.3pp	7.5%-1.7pp	9.2%
Net Margin	8.5%-0.4pp	8.9%+1.4pp	7.5%+1.0pp	6.5%+2.0pp	4.5%+5.5pp	-1.0%-1.6pp	0.5%-4.2pp	4.8%+1.0pp	3.8%+0.4pp	3.3%-1.1pp	4.4%-0.1pp	4.5%+0.8pp	3.7%-1.3pp	5.0%-1.4pp	6.4%
Return on Equity	8.1%-0.6pp	8.7%+0.9pp	7.8%+1.3pp	6.5%+1.9pp	4.7%+5.7pp	-1.0%-1.6pp	0.6%-3.9pp	4.5%+0.4pp	4.1%0.0pp	4.0%-1.1pp	5.1%-0.2pp	5.3%+1.2pp	4.1%-1.1pp	5.2%-1.3pp	6.5%
Return on Assets	4.8%-0.2pp	5.0%+0.9pp	4.1%-0.4pp	4.5%+1.5pp	2.9%+3.5pp	-0.6%-0.9pp	0.3%-2.3pp	2.6%+0.1pp	2.5%+0.3pp	2.1%-0.9pp	3.1%0.0pp	3.1%+0.8pp	2.3%-0.5pp	2.8%-2.4pp	5.2%
Current Ratio	4.34+0.1x	4.27-1.2x	5.45+3.0x	2.40+0.4x	2.04-0.3x	2.32-0.2x	2.50+0.1x	2.45-0.3x	2.730.0x	2.76+0.4x	2.32-0.2x	2.550.0x	2.53+0.3x	2.22-0.8x	3.05
Debt-to-Equity	0.46-0.1x	0.53-0.2x	0.68+0.5x	0.16-0.1x	0.23-0.1x	0.36-0.1x	0.45+0.1x	0.400.0x	0.38-0.2x	0.63+0.2x	0.42-0.1x	0.49-0.1x	0.590.0x	0.60+0.5x	0.09
FCF Margin	14.2%+0.5pp	13.7%+4.9pp	8.8%+2.8pp	6.0%-5.1pp	11.1%-1.3pp	12.4%+12.4pp	0.0%-2.7pp	2.6%-0.7pp	3.3%-0.1pp	3.4%0.0pp	3.4%-0.4pp	3.8%+5.6pp	-1.8%+2.7pp	-4.5%+2.5pp	-7.0%

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Gross Margin	51.4%+3.0pp	48.4%-1.2pp	49.6%+1.1pp	48.5%+0.3pp	48.2%-0.2pp	48.4%-0.3pp	48.7%+2.4pp	46.4%
Operating Margin	14.4%+2.9pp	11.6%-2.2pp	13.8%+2.7pp	11.1%-1.2pp	12.3%+0.7pp	11.6%+1.3pp	10.3%-0.7pp	11.0%
Net Margin	9.3%-1.5pp	10.7%+1.1pp	9.7%+2.4pp	7.2%-1.3pp	8.5%0.0pp	8.5%+0.6pp	7.9%-0.5pp	8.4%
Return on Equity	2.3%-0.2pp	2.5%+0.1pp	2.4%+0.6pp	1.8%-0.4pp	2.2%+0.1pp	2.1%+0.1pp	2.0%-0.1pp	2.1%
Return on Assets	1.4%-0.2pp	1.5%+0.1pp	1.4%+0.4pp	1.1%-0.2pp	1.3%0.0pp	1.2%+0.1pp	1.2%0.0pp	1.2%
Current Ratio	4.20-0.9x	5.08+0.7x	4.34+0.1x	4.28+0.2x	4.09-0.8x	4.87+0.6x	4.27-1.1x	5.36
Debt-to-Equity	0.440.0x	0.450.0x	0.460.0x	0.480.0x	0.490.0x	0.510.0x	0.530.0x	0.57
FCF Margin	12.4%+5.9pp	6.5%-12.3pp	18.8%+5.1pp	13.7%-4.5pp	18.2%+12.7pp	5.5%-12.9pp	18.4%+7.2pp	11.2%

Similar Companies

Teleflex Inc TFX

$5.9B

Bausch + Lomb Corporation BLCO

$6.2B

Repligen RGEN

$10.2B

Stevanato Group S P A STVN

$6.1B

Icu Medical ICUI

$4.5B

Where Merit Med Sys Inc Ranks

Frequently Asked Questions

What is Merit Med Sys Inc's annual revenue?

Merit Med Sys Inc (MMSI) reported $1.5B in total revenue for fiscal year 2025. This represents a 11.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Merit Med Sys Inc's revenue growing?

Merit Med Sys Inc (MMSI) revenue grew by 11.8% year-over-year, from $1.4B to $1.5B in fiscal year 2025.

Is Merit Med Sys Inc profitable?

Yes, Merit Med Sys Inc (MMSI) reported a net income of $128.5M in fiscal year 2025, with a net profit margin of 8.5%.

What is Merit Med Sys Inc's EBITDA?

Merit Med Sys Inc (MMSI) had EBITDA of $307.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Merit Med Sys Inc have?

As of fiscal year 2025, Merit Med Sys Inc (MMSI) had $446.4M in cash and equivalents against $734.0M in long-term debt.

What is Merit Med Sys Inc's gross margin?

Merit Med Sys Inc (MMSI) had a gross margin of 48.7% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Merit Med Sys Inc's operating margin?

Merit Med Sys Inc (MMSI) had an operating margin of 12.2% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Merit Med Sys Inc's net profit margin?

Merit Med Sys Inc (MMSI) had a net profit margin of 8.5% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Merit Med Sys Inc's return on equity (ROE)?

Merit Med Sys Inc (MMSI) has a return on equity of 8.1% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Merit Med Sys Inc's free cash flow?

Merit Med Sys Inc (MMSI) generated $215.7M in free cash flow during fiscal year 2025. This represents a 16.2% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Merit Med Sys Inc's operating cash flow?

Merit Med Sys Inc (MMSI) generated $297.4M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Merit Med Sys Inc's total assets?

Merit Med Sys Inc (MMSI) had $2.7B in total assets as of fiscal year 2025, including both current and long-term assets.

What are Merit Med Sys Inc's capital expenditures?

Merit Med Sys Inc (MMSI) invested $81.7M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Merit Med Sys Inc spend on research and development?

Merit Med Sys Inc (MMSI) invested $97.4M in research and development during fiscal year 2025.

How many shares does Merit Med Sys Inc have outstanding?

Merit Med Sys Inc (MMSI) had 59M shares outstanding as of fiscal year 2025.

What is Merit Med Sys Inc's current ratio?

Merit Med Sys Inc (MMSI) had a current ratio of 4.34 as of fiscal year 2025, which is generally considered healthy.

What is Merit Med Sys Inc's debt-to-equity ratio?

Merit Med Sys Inc (MMSI) had a debt-to-equity ratio of 0.46 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Merit Med Sys Inc's return on assets (ROA)?

Merit Med Sys Inc (MMSI) had a return on assets of 4.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Merit Med Sys Inc's Altman Z-Score?

Merit Med Sys Inc (MMSI) has an Altman Z-Score of 4.49, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Merit Med Sys Inc's Piotroski F-Score?

Merit Med Sys Inc (MMSI) has a Piotroski F-Score of 7 out of 9, indicating strong financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Merit Med Sys Inc's earnings high quality?

Merit Med Sys Inc (MMSI) has an earnings quality ratio of 2.31x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Merit Med Sys Inc cover its interest payments?

Merit Med Sys Inc (MMSI) has an interest coverage ratio of 6.98x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Merit Med Sys Inc?

Merit Med Sys Inc (MMSI) scores 69 out of 100 on our Financial Health Score, indicating strong standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.